Core Viewpoint - CRISPR Therapeutics is set to report its fourth-quarter and full-year 2024 earnings, with expectations of a sales figure of $10.13 million and a loss of $1.15 per share, while the loss per share estimate for 2025 has increased from $5.17 to $5.21 in the last month [1][11]. Earnings Performance - The company has shown a decent performance over the past four quarters, beating earnings estimates in three out of four quarters, with an average surprise of 100.64% [4][5]. - In the last reported quarter, CRISPR's earnings exceeded expectations by 24.06% [4]. Earnings Estimates - CRISPR Therapeutics has an Earnings ESP of +8.09%, with the most accurate estimate at a loss of $1.06 per share compared to the Zacks Consensus Estimate of a loss of $1.15 [7][6]. Revenue Drivers - The company's revenue is currently bolstered by grants and collaboration revenues from its partnership with Vertex Pharmaceuticals [9]. - The recently approved gene therapy, Casgevy, is expected to contribute $10 million in sales for CRISPR in the fourth quarter, marking the first marketed product in its portfolio [10][11]. Pipeline Development - CRISPR is advancing its pipeline with two next-generation CAR-T therapy candidates, CTX112 and CTX131, currently in phase I/II studies, along with two in-vivo candidates, CTX310 and CTX320, in separate phase I clinical studies [12][13]. Stock Performance and Valuation - Over the past year, CRISPR's stock has declined by 41%, underperforming the industry and broader market indices [15][16]. - The company's shares trade at a price/book ratio of 1.79, which is lower than the industry average of 3.71, indicating attractive valuation [18]. Investment Thesis - With the approval of Casgevy, CRISPR has overcome a significant hurdle regarding revenue generation, although the treatment process may delay revenue recognition [20]. - The partnership with Vertex provides a competitive advantage over rivals, as CRISPR is the first to market an approved CRISPR-based therapy [21]. Future Outlook - The upcoming earnings report is anticipated to be a major catalyst for CRISPR, as it will be the first quarter to record revenues from Casgevy, providing insights into market demand and potential [23].

Readers may recall my last article from October 2024 – a deep dive into CRISPR Therapeutics AG (NASDAQ: CRSP ) – in which I outlined several catalysts for the company and its stock going forward. Giving it a buyI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewards. I believe the key to creating wea ...

CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%. Meanwhile, the Dow lost 0.31%, and the Nasdaq, a tech-heavy index, lost 0.51%.The company's stock has climbed by 6.22% in the past month, exceeding the Medical sector's gain of 3.2% and the S&P 500's gain of 1.67%.Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings d ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 2:00 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile, the Dow experienced a drop of 0.32%, and the technology-dominated Nasdaq saw a decrease of 0.5%.Heading into today, shares of the company had gained 7.69% over the past month, outpacing the Medical sector's gain of 1.54% and the S&P 500's gain of 2.52% in that time.The investment community will be closely mon ...

Stock Performance - CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20, driven by higher trading volume compared to a typical session [1] - The stock has gained 1.4% over the past four weeks [1] - Tarsus Pharmaceuticals, Inc. (TARS) finished the last trading session 2.9% higher at $48.11, but has returned -13.5% over the past month [3] Financial Expectations - CRISPR Therapeutics is expected to post a quarterly loss of $1.20 per share, representing a year-over-year change of -209.1% [2] - Revenues are expected to be $10.83 million, down 94.6% from the year-ago quarter [2] - The consensus EPS estimate for CRISPR Therapeutics has remained unchanged over the last 30 days [3] - Tarsus Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.70, representing a year-over-year change of +46.6% [4] Strategic Priorities - CRISPR Therapeutics outlined key strategic priorities related to the ongoing launch of Casgevy and certain pipeline goals for 2025, which may have driven the recent share price rally [1] Industry and Rankings - CRISPR Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry [3] - The stock currently carries a Zacks Rank 3 (Hold) [3] - Tarsus Pharmaceuticals currently boasts a Zacks Rank of 2 (Buy) [4]

Company Overview - CRISPR Therapeutics (CRSP) shares have lost more than 30% in the past year, despite a surge at the start of 2024 due to FDA approval of its gene therapy Casgevy [1] - The company has yet to record revenues from Casgevy sales, and a lack of pipeline updates beyond Casgevy's approval has disappointed investors [1] - CRSP's stock has underperformed the industry, sector, and S&P 500, losing nearly 34% compared to the industry's 14% decline [13][15] Casgevy Approval and Market Potential - Casgevy, the first CRISPR-based gene-editing therapy, was approved in late 2023/early 2024 for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in the US and Europe [4] - The therapy addresses a significant unmet medical need for an estimated 35,000 patients with severe SCD or TDT in the US and Europe, with additional patients in Bahrain and Saudi Arabia [5] - Vertex Pharmaceuticals, CRSP's collaborator, has reported a strong launch for Casgevy, with collaboration revenues expected to be recorded in Q4 2024 [6] Pipeline Development - CRSP is developing next-generation CAR-T therapy candidates CTX112 and CTX131, which have shown higher CAR T cell expansion and functional persistence in phase I/II studies [7] - The company is also focusing on in-vivo candidates CTX310 and CTX320, targeting cardiovascular disease, with plans to expand the in-vivo pipeline by 2025 [8][9] Competitive Landscape - Beam Therapeutics is developing BEAM-101 for SCD and TDT using CRISPR technology, while Intellia Therapeutics leads in in-vivo CRISPR-based therapies for various indications [11][12] Financial Performance and Valuation - CRSP's shares are trading below its 50-day and 200-day moving averages, with a price-to-book (P/B) ratio of 1.77, lower than the industry's 3.42 [13][16] - The company has a strong cash balance of $1.9 billion as of September 2024, supporting its operations and pipeline development [23] Future Catalysts - The next major catalyst for CRSP will be its Q4 2024 results, which will provide insights into Casgevy's market potential and demand [21] - Analysts have improved their 2025 loss per share estimates for CRSP from $5.23 to $5.19 in the past 60 days, reflecting a more optimistic outlook [18]

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

Key Points Company and Industry Overview 1. **Company Name and Stock Symbol**: CRISPR Therapeutics AG (NASDAQ: CRSP) [2] 2. **Industry**: Biotechnology, specifically gene editing and gene therapy [3] 3. **Business Segments**: Hemoglobinopathies (heme), oncology, autoimmune, cardiovascular medicines, and rare diseases [3] Pipeline and Products 4. **Clinical Programs**: Five programs in various disease areas, including oncology, autoimmune, cardiovascular, and rare diseases [3] 5. **Preclinical Programs**: Ten preclinical programs with promising potential [3] 6. **Approved Drug**: CASGEVY, a hemoglobinopathy treatment, partnered with Vertex [4] Financial and Business Performance 7. **Revenue**: Not specified in the provided text [3] 8. **Business Model**: Divided into four franchises, with hemoglobinopathies being the core [3] Future Outlook 9. **Outlook**: One of the most consequential years in the company's journey [5] 10. **Risk Factors**: Encourages participants to visit the company's website for a full risk list [6] Additional Information 11. **Conference**: 43rd Annual JPMorgan Healthcare Conference [2] 12. **Date**: January 14, 2025 [2] 13. **Time**: 5:15 PM ET [2] 14. **Participants**: Samartha Kulkarni (CEO and Chairman), Fanchen Zhou (JPMorgan) [2]

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock that could deliver huge gains in a defined time frame.Citing positive developments in its development programs, analysts from a couple of investment banks think CRISPR Therapeutics (CRSP -2.12%) could more than double your money in the year ahead.But before committing any amount of your own money to this stock, it's important to remember the analysts who recommended it have very little t ...